针对缺血性中风和相关慢性疼痛的目标基因的多维多态综合性研究
Yuanlin Wang1,2, Dan Liu3, Shuai Wang4
1Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin, China. wyl1996@tmu.edu.cn.
Cellular and molecular neurobiology
|August 24, 2025
概括
这项研究确定S100a6是将缺血性中风与慢性疼痛联系起来的关键基因. 激活S100a6显示出对中风的保护作用,并减少疼痛,这表明它是潜在的药物点.
科学领域:
- 神经科学
- 免疫学
- 遗传学
背景情况:
- 慢性疼痛是缺血性中风的常见并发症.
- 了解缺血性中风的免疫相关细胞死亡对于管理其后果至关重要.
研究的目的:
- 在缺血性中风中识别与免疫相关的细胞死亡目标基因.
- 探索这些基因在慢性疼痛发展中的作用.
- 评估S100a6作为潜在的治疗标.
主要方法:
- 来自小鼠MCAO模型的mRNA和microRNA转录组数据的分析.
- 大脑组织的单细胞和空间转录组分析.
- 用于因果推断和药物标评估的全基因组关联研究 (GWAS),eQTL和门德尔随机化 (MR).
- 在动物模型中验证聚合酶链反应 (PCR).
主要成果:
- 五个核心mRNAs (S100a6,Anxa3,Ncf4,Capg,Arpc1b) 和一个微RNA (miR-298-5p) 被确定为与免疫相关的细胞死亡的生物标志物.
- S100a6因其参与CD4+γδT细胞分化和缺血性中风后免疫激活的重要作用而受到重视.
- 激活S100a6可以将缺血性中风的可能性降低23- 54%,并保护神经元功能.
结论:
- 在缺血性中风和相关的慢性疼痛中,S100a6具有因果保护作用.
- S100a6被认为是缺血性中风和慢性疼痛的有希望的治疗点.
- 这项研究阐明了细胞死亡,免疫反应和中风后的神经复杂性之间的复杂关系.
相关概念视频
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Analgesia and Pain Management
3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121


